Pharma & Healthcare Taxation & Incentives in Denmark

Denmark is one of Europe';s most attractive jurisdictions for pharmaceutical and healthcare investment, combining a stable corporate tax environment with targeted incentives for research-intensive businesses. Companies that understand the full architecture of Danish tax law - from R&D super-deductions to the IP box regime and sector-specific VAT rules - can significantly reduce their effective tax burden while remaining fully compliant. Those that enter the Danish market without specialist guidance, however, routinely leave substantial value on the table or trigger costly disputes with the Danish Tax Agency (Skattestyrelsen). This article maps the complete tax and incentives landscape for pharma and healthcare operators in Denmark, covering corporate income tax, R&D reliefs, the IP box, transfer pricing, VAT and customs, and the practical steps required to capture each benefit.

Denmark imposes corporate income tax (selskabsskat) at a flat rate of 22% on the worldwide income of Danish-resident companies. For pharma and healthcare groups, this headline rate is the starting point, but the effective rate can be reduced materially through the layering of available deductions and incentive regimes.

The Danish Corporation Tax Act (Selskabsskatteloven) governs the taxation of resident companies and permanent establishments. Under its general provisions, all ordinary business expenses - including salaries, clinical trial costs, regulatory fees and manufacturing overheads - are deductible in the year they are incurred, provided they satisfy the arm';s-length and business-purpose tests. Capital expenditure on laboratory equipment and production assets is depreciated under the Tax Depreciation and Amortisation Act (Afskrivningsloven), which permits accelerated depreciation of up to 25% per year on a declining-balance basis for most tangible assets used in production.

A non-obvious risk for international groups is the interaction between Danish thin-capitalisation rules and the financing of Danish pharma subsidiaries. The Interest Limitation Act (Rentefradragsbegrænsningsloven) caps net financing costs at 22% of EBITDA (the EBITDA rule) and also applies an absolute cap under the asset test. Groups that fund Danish operations primarily through intercompany debt - a common structure in pharma - must model these limitations carefully before finalising their capital structure, as disallowed interest is not carried forward indefinitely.

Losses may be carried forward without time limit under the Corporation Tax Act, but the annual offset is capped at DKK 8.7 million plus 60% of taxable income exceeding that threshold. For early-stage biotech or medtech companies with prolonged pre-revenue periods, this limitation means that accumulated losses may take many years to utilise fully, affecting the net present value of the tax shield.

In practice, it is important to consider that Denmark operates a mandatory joint taxation (sambeskatning) regime for groups of companies. Danish-resident group members are automatically included in a domestic joint taxation group, allowing losses from one entity to offset profits in another within the same income year. International groups may elect for international joint taxation (international sambeskatning), which draws all worldwide group members into the Danish tax base - a powerful tool in some structures but one that carries significant complexity and risk if the global group includes high-profit entities in other jurisdictions.

Research and development expenditure is the single most important tax lever for pharma and healthcare companies in Denmark. The Danish R&D super-deduction regime, introduced progressively and now embedded in the Corporation Tax Act (Selskabsskatteloven, section 8 B and related provisions), allows qualifying R&D costs to be deducted at a rate exceeding 100% of actual expenditure.

The super-deduction rate has been phased upward in recent years and currently stands at 110%, meaning that for every DKK 100 of qualifying R&D spend, DKK 110 is deductible against taxable income. This translates to a cash tax saving of approximately DKK 24.2 per DKK 100 of R&D expenditure at the 22% corporate rate - a meaningful uplift for capital-intensive drug development programmes.

Qualifying expenditure includes:

• Salaries and social contributions for researchers and clinical staff directly engaged in R&D
• Costs of contracted R&D performed by Danish or EU/EEA universities and research institutions
• Direct material costs consumed in experimental or development work
• Costs of obtaining regulatory approvals that are integral to the R&D process

A common mistake made by international pharma groups is treating all expenditure incurred in a Danish laboratory as automatically qualifying. Danish tax law draws a sharp distinction between research (systematic investigation aimed at new knowledge) and routine testing, quality control, post-approval pharmacovigilance and production scale-up. Costs falling on the wrong side of this line are deductible at 100% as ordinary business expenses but do not attract the super-deduction uplift. Skattestyrelsen scrutinises R&D claims closely, and misclassification is one of the most frequent triggers for tax audits in the sector.

For loss-making companies - a common position for early-stage biotech and medtech firms - Denmark offers a cash refund mechanism under the Corporation Tax Act. Companies that cannot utilise the R&D super-deduction against current taxable income may claim a cash payment from the Danish state equal to the tax value of the deduction, subject to a cap on the qualifying R&D expenditure base. The refund is paid within a defined period after the tax return is filed, providing a genuine liquidity benefit for pre-revenue companies. This mechanism is particularly valuable for Danish biotech start-ups and for foreign groups that have established Danish R&D subsidiaries ahead of commercial operations.

To receive a checklist of qualifying R&D expenditure categories and documentation requirements for the Danish super-deduction, send a request to info@vlolawfirm.com

The procedural requirements for claiming the super-deduction and cash refund are demanding. Companies must maintain contemporaneous documentation demonstrating the scientific or technological uncertainty addressed by each project, the systematic methodology applied, and the direct nexus between each cost item and the qualifying activity. Documentation assembled retrospectively - a frequent shortcut taken by companies under time pressure - is routinely rejected by Skattestyrelsen and may result in the entire claim being disallowed, together with interest on underpaid tax.

Denmark operates a patent box regime (patentboksordningen) under the Corporation Tax Act that reduces the effective tax rate on qualifying intellectual property income. The regime applies to income derived from patents, supplementary protection certificates, and certain other registered rights that result from qualifying R&D activities conducted by the company or on its behalf.

Under the Danish IP box, qualifying income is taxed at an effective rate of approximately 12% rather than the standard 22% corporate rate. The regime follows the OECD-endorsed nexus approach, meaning that the proportion of IP income eligible for the reduced rate is linked to the proportion of qualifying R&D expenditure incurred directly by the Danish entity relative to total development costs for the relevant IP asset. Groups that outsource significant R&D to related parties outside Denmark will find their nexus fraction - and therefore their IP box benefit - reduced accordingly.

Qualifying income includes royalties received from third parties and related parties, gains on the disposal of qualifying IP, and embedded royalties in product sales where the IP contributes to the product';s value. The last category is particularly relevant for integrated pharma manufacturers that sell finished pharmaceutical products incorporating patented molecules or formulations. Calculating the embedded royalty requires a transfer pricing analysis, and the methodology must be defensible under both Danish and OECD standards.

A non-obvious risk in the Danish IP box context is the interaction with controlled foreign corporation (CFC) rules under the Corporation Tax Act (Selskabsskatteloven, section 32). If a Danish parent holds IP through a foreign subsidiary that qualifies as a CFC, the CFC income - including IP income - is attributed back to the Danish parent and taxed at the standard 22% rate, effectively negating the IP box benefit at the subsidiary level. Groups considering offshore IP holding structures must model the CFC implications carefully before implementation.

The practical economics of the IP box are most compelling for companies with a substantial and growing royalty stream or a pipeline of patentable assets nearing commercialisation. For a Danish pharma company generating DKK 100 million in annual patent royalties, the difference between the standard rate and the IP box rate represents a tax saving of approximately DKK 10 million per year - a figure that justifies significant investment in structuring and compliance.

Many underappreciate the importance of timing in IP box planning. The nexus fraction is calculated on a cumulative basis over the life of the IP asset, meaning that R&D expenditure incurred before the regime was adopted, or before the company elected into the regime, may not count toward the qualifying fraction. Companies that delay structuring their R&D activities to maximise the nexus fraction will find that their IP box benefit is permanently impaired for assets already in development.

Transfer pricing (intern afregning) is the area of Danish tax law that generates the greatest volume of disputes between pharma and healthcare multinationals and Skattestyrelsen. The Danish Transfer Pricing Act (Skattekontrolloven, sections 37-46) requires that all transactions between related parties be priced on arm';s-length terms, and imposes detailed documentation obligations on groups meeting defined size thresholds.

Denmark has adopted the OECD Transfer Pricing Guidelines in full, and Skattestyrelsen applies them rigorously. The most contested transaction types in the pharma sector are:

• Royalties for the use of patented molecules, formulations and manufacturing know-how
• Cost-sharing arrangements for global R&D programmes
• Distribution margins for Danish entities acting as limited-risk distributors
• Management fees and shared service charges from group headquarters

A common mistake made by international groups is treating Denmark as a routine market jurisdiction and applying a thin distribution margin to the Danish entity without adequate functional analysis. Danish tax authorities have consistently challenged structures where the Danish entity performs significant functions - including regulatory affairs, market access negotiations and pharmacovigilance - that are not reflected in the transfer price. Where Skattestyrelsen makes a transfer pricing adjustment, it also imposes interest on the underpaid tax, which accrues from the original due date and can be substantial for adjustments covering multiple years.

The documentation requirements under the Skattekontrolloven are extensive. Groups with Danish entities must prepare a master file (masterfil) and a local file (lokalfil) annually, following the OECD three-tier documentation standard. The local file must include a detailed functional analysis, a description of the selected transfer pricing method, a comparability analysis with benchmarking data, and financial data supporting the tested party';s results. Documentation must be submitted to Skattestyrelsen within 60 days of a request, and failure to comply shifts the burden of proof to the taxpayer in any subsequent dispute.

Country-by-country reporting (CbCR) obligations apply to Danish-parented groups with consolidated revenue exceeding DKK 5.6 billion. For groups below this threshold, the CbCR obligation may still arise if the ultimate parent is required to file in another jurisdiction and has designated the Danish entity as a surrogate filer.

Advance pricing agreements (forhåndstilsagn om transfer pricing) are available in Denmark and provide certainty for a defined period, typically three to five years. The process is resource-intensive and requires detailed disclosure of the group';s global structure and the proposed pricing methodology, but for groups with high-value intercompany transactions - particularly IP royalties - the certainty obtained is often worth the investment. Bilateral APAs, negotiated between Skattestyrelsen and a counterpart tax authority under a relevant tax treaty, eliminate the risk of double taxation and are the preferred tool for the most complex arrangements.

To receive a checklist of transfer pricing documentation requirements for pharma and healthcare groups operating in Denmark, send a request to info@vlolawfirm.com

Value added tax (merværdiafgift, or moms) in Denmark is levied at the standard rate of 25%, one of the highest in the EU. The interaction between Danish VAT rules and the pharma and healthcare sector is complex, because the sector spans both taxable and exempt supplies, and the correct VAT treatment of a given transaction depends on its precise legal and commercial characterisation.

Under the Danish VAT Act (Momsloven, section 13), the supply of medical treatment and closely related services by licensed healthcare professionals is exempt from VAT. This exemption covers hospital services, medical consultations, dental treatment, physiotherapy and similar activities. The exemption is narrow and does not extend to cosmetic procedures without a therapeutic purpose, wellness services, or the supply of pharmaceutical products as such.

The sale of prescription and over-the-counter pharmaceutical products is subject to VAT at the standard 25% rate. This creates a structural input VAT recovery issue for hospitals, clinics and other healthcare providers that make predominantly exempt supplies: they cannot recover the VAT charged on their pharmaceutical purchases, which becomes an irrecoverable cost embedded in the healthcare system. International pharma companies selling into the Danish healthcare market should be aware that their Danish hospital customers operate under this constraint, as it affects pricing negotiations and the total cost of treatment calculations used in health technology assessments.

For pharma manufacturers with Danish production facilities, the VAT position is generally more straightforward: manufacturing and wholesale distribution are fully taxable activities, and input VAT on production costs is recoverable in full. The complexity arises at the boundary between taxable manufacturing and exempt healthcare services - for example, where a pharma company also operates a patient support programme or a diagnostic service that could be characterised as medical treatment.

Customs duties apply to pharmaceutical raw materials, active pharmaceutical ingredients (APIs) and finished products imported into Denmark from outside the EU. Denmark applies the EU Common Customs Tariff, and the applicable duty rates depend on the tariff classification of the goods. Many pharmaceutical products benefit from duty suspensions or reduced rates under the EU';s pharmaceutical tariff regime, but the classification of novel biologics, biosimilars and combination products is frequently contested, and classification errors can result in significant retrospective duty assessments.

Denmark also imposes a pharmaceutical levy (lægemiddelafgift) on the wholesale turnover of medicinal products sold in Denmark. The levy is administered by the Danish Medicines Agency (Lægemiddelstyrelsen) and is calculated as a percentage of wholesale prices. The rate varies depending on the product category and the level of reimbursement. This levy is deductible for corporate income tax purposes but is not recoverable as VAT, making it a genuine cost of doing business in the Danish pharmaceutical market.

A non-obvious risk for international groups entering the Danish market through a Danish distributor is the allocation of the pharmaceutical levy obligation between the manufacturer and the distributor. The contractual arrangements must clearly address who bears this cost, as ambiguity has led to disputes in practice.

Understanding how the Danish tax and incentives framework applies in practice requires examining concrete business situations. Three scenarios illustrate the range of issues that arise.

Scenario one: a US biotech establishing a Danish R&D subsidiary. A US-listed biotech company establishes a wholly owned Danish subsidiary to conduct Phase II clinical trials for a novel oncology compound. The Danish entity employs 40 researchers and contracts additional work to the University of Copenhagen. The subsidiary is loss-making and has no current taxable income. In this scenario, the Danish entity can claim the R&D cash refund mechanism, receiving a cash payment from the Danish state equal to the tax value of the super-deduction on qualifying expenditure. The US parent must ensure that the intercompany arrangements - including any cost-sharing agreement and the allocation of IP ownership - are documented at arm';s length from inception, because Skattestyrelsen will scrutinise these arrangements if the compound reaches commercialisation and generates significant royalty income. The risk of inaction on transfer pricing documentation is acute: if the IP is transferred to a non-Danish entity after development without a properly documented arm';s-length price, Skattestyrelsen may challenge the exit valuation and assess Danish tax on the full value of the developed IP.

Scenario two: a European pharma group with Danish IP holding and manufacturing. A European pharma group holds patents for a blockbuster cardiovascular drug in a Danish IP holding company and licenses them to manufacturing and distribution affiliates across Europe. The Danish IP holding company elects into the IP box regime and applies the nexus fraction based on R&D conducted in Denmark and at contracted Danish research institutions. The group must maintain meticulous records of all R&D expenditure by project and by entity to support the nexus calculation, and must ensure that the royalty rates charged to affiliates are consistent with the arm';s-length standard. The loss caused by an incorrect nexus calculation - for example, by including non-qualifying expenditure in the numerator - is a permanent reduction in the IP box benefit for the life of the patent, not merely a timing difference.

Scenario three: a Danish medtech start-up seeking to scale internationally. A Danish-founded medtech company has developed a Class IIb medical device and is preparing to commercialise it across the EU and in the US. The company has accumulated significant R&D losses and is considering whether to retain IP ownership in Denmark or transfer it to a holding company in a lower-tax jurisdiction before commercialisation. The Danish exit tax rules under the Corporation Tax Act (Selskabsskatteloven, section 8 D) impose a deemed disposal at market value on any IP transferred out of Danish tax jurisdiction. The market value at the point of transfer - which Skattestyrelsen will assess using a discounted cash flow or comparable uncontrolled transaction methodology - may be substantial if the device has already received regulatory clearance. The cost of non-specialist advice at this stage can be enormous: a poorly timed or poorly valued IP transfer can trigger a Danish tax liability that exceeds the entire projected tax saving from the offshore structure.

What is the most significant practical risk for a foreign pharma company entering Denmark without local tax advice?

The most significant risk is misclassifying expenditure under the R&D super-deduction regime and simultaneously failing to establish arm';s-length transfer pricing documentation from the outset. Both errors are difficult and expensive to correct retrospectively. Skattestyrelsen conducts sector-specific audits of pharma and healthcare companies, and the combination of an unsupported R&D claim and inadequate transfer pricing documentation in the same audit cycle can result in simultaneous adjustments across multiple tax years, compounded by interest charges that accrue from the original due date. The practical consequence is that a company that believed it had a favourable tax position may face a material liability that was entirely avoidable with proper structuring.

How long does it take to obtain an advance pricing agreement in Denmark, and what does it cost?

A unilateral APA with Skattestyrelsen typically takes between 12 and 24 months from the initial application to the issuance of a binding agreement, depending on the complexity of the transaction and the responsiveness of both parties. A bilateral APA, involving negotiation with a counterpart tax authority under a double tax treaty, generally takes longer - often 24 to 48 months. The direct costs include professional fees for preparing the application and supporting documentation, which for a complex pharma royalty arrangement can run into the mid-to-high tens of thousands of euros. The indirect cost is the management time required to respond to Skattestyrelsen';s information requests. For groups with annual intercompany transactions in the tens of millions of euros, the certainty obtained from a bilateral APA typically justifies this investment.

When should a pharma company consider international joint taxation in Denmark rather than limiting its Danish tax group to domestic entities?

International joint taxation (international sambeskatning) is worth considering when the Danish group has significant losses that cannot be offset against Danish profits within a reasonable time horizon, and when the global group includes profitable entities in jurisdictions that do not impose CFC-type charges on Danish-source income. The key constraint is that electing international joint taxation draws all worldwide group members into the Danish tax base for a minimum period of ten years, and the election cannot be reversed without triggering a recapture of all previously utilised foreign losses. For most pharma multinationals, the risk of locking in a ten-year commitment - particularly given the volatility of clinical development outcomes - outweighs the benefit of accelerating loss utilisation. The election is most appropriate for groups with a stable, profitable global structure and a Danish entity with large, predictable losses from long-cycle R&D programmes.

Denmark';s tax and incentives framework for pharma and healthcare companies is genuinely competitive, but its value is realised only by operators who engage with it systematically. The R&D super-deduction, IP box regime, cash refund mechanism and joint taxation rules each require careful structuring and rigorous documentation to deliver their intended benefits. Transfer pricing and VAT compliance add further layers of complexity that are specific to the sector and to the Danish regulatory environment. Companies that approach Denmark as a straightforward market jurisdiction - rather than as a jurisdiction with a sophisticated and actively enforced tax system - consistently underperform relative to their peers.

Our law firm VLO Law Firms has experience supporting clients in Denmark on pharma and healthcare taxation and incentives matters. We can assist with R&D super-deduction claims, IP box structuring, transfer pricing documentation, advance pricing agreement applications, VAT compliance for healthcare operations, and exit tax planning for IP transfers. To receive a consultation, contact: info@vlolawfirm.com

To receive a checklist of key compliance steps and incentive planning actions for pharma and healthcare companies operating in Denmark, send a request to info@vlolawfirm.com